GlassScriptPhysician profile
Nicole Ann Ferrill
NPI 1083021372
$4,682.32
in general payments reported to CMS, 2019-2025
30 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.71 · 2023: $1,092 · 2024: $1,738 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,379 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,379.13 |
| Education | $235.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $900.20 | 2022-2025 | Wakix |
| Inspire Medical Systems, INC. | $733.54 | 2023-2025 | Inspire |
| Pfizer INC. | $729.39 | 2023-2025 | |
| Abbvie INC. | $443.41 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $237.59 | 2023-2025 | Austedo Xr, Austedo Xr |
| Argenx US, INC. | $212.78 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $171.76 | 2023-2024 | Amyvid, Reyvow, Emgality |
| Novartis Pharmaceuticals Corporation | $159.48 | 2023-2025 | |
| Axsome Therapeutics, INC. | $147.16 | 2023-2025 | Sunosi |
| Lundbeck LLC | $125.42 | 2023-2024 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $106.16 | 2024-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $102.86 | 2024 | |
| Abbott Laboratories | $69.70 | 2024-2025 | Infinity |
| Sk Life Science, INC. | $65.15 | 2024-2025 | |
| Tanabe Pharma America, INC. | $56.67 | 2024-2025 | Radicava |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $45.76 | 2024-2025 | Vumerity, Spinraza, Qalsody |
| Kyowa Kirin, INC. | $42.25 | 2023 | Nourianz |
| Itamar Medical INC | $40.23 | 2023 | Watchpatone |
| Genzyme Corporation | $30.98 | 2025 | |
| Eisai INC. | $27.94 | 2022 | |
| Alexion Pharmaceuticals, INC. | $27.26 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $24.92 | 2025 | Hyqvia |
| Ge Healthcare | $24.71 | 2024 | |
| Amneal Pharmaceuticals LLC | $23.57 | 2022 | |
| Livanova USA, INC. | $23.31 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $22.93 | 2023 | Ponvory |
| Genentech USA, INC. | $22.87 | 2025 | Ocrevus Zunovo |
| Catalyst Pharmaceuticals, INC. | $22.56 | 2024 | |
| Emd Serono, INC. | $22.17 | 2025 | |
| Philips North America LLC | $19.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Ferrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.